AbCellera Biologics upgraded by The Benchmark Company with a new price target
$ABCL
Pharmaceuticals and Biotechnology
Health Care
The Benchmark Company upgraded AbCellera Biologics from Hold to Buy and set a new price target of $9.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2024 | Buy → Hold | The Benchmark Company | |
| 2/22/2024 | $9.00 | Hold → Buy | The Benchmark Company |
| 12/5/2023 | $6.00 | Overweight | KeyBanc Capital Markets |
| 11/6/2023 | Buy → Hold | The Benchmark Company | |
| 10/13/2023 | $20.00 | Overweight | Piper Sandler |
| 2/28/2023 | Outperform | Cowen | |
| 12/15/2022 | $30.00 | Buy | Goldman |
| 11/16/2022 | $29.00 | Buy | Truist |